MKI67 and neuroendocrine neoplasm: At a 2009 European Neuroendocrine Society Consensus Conference, an international group of experts proposed a grading system (G1–G3) utilizing a combination of Ki-67 and mitoses to stratify patients with GI neuroendocrine tumours [3].